Mounjaro®
Starting from £179.99/mo
Start journey Learn moreStop a GLP-1 weight loss injection and, for most people, appetite returns within weeks and some of the lost weight comes back over the following months. That is not a sign the medicine failed — it is how these medicines work, and it has real implications for how you plan your treatment. Because Mounjaro and Wegovy are prescription-only medicines, any decision about stopping or pausing should be made with your prescriber, not unilaterally.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
You've been on treatment for months. The pen in the fridge door is the last one, and you're wondering whether to reorder or call it done. It's a question our prescribers hear regularly, and it deserves a straight answer.
When you stop a GLP-1 or dual GIP/GLP-1 medicine such as Mounjaro or Wegovy, the active ingredient clears your body over one to two weeks. As it does, the signals it was sending (reduced appetite, slower gastric emptying, a steadier sense of fullness) gradually switch off. Hunger typically returns to something closer to your pre-treatment baseline. For many people, that shift happens faster than they expect.
Clinical trial extension data bear this out. The STEP 1 trial of semaglutide 2.4mg, published in the New England Journal of Medicine, included a one-year follow-up after participants stopped the medicine. On average, about two thirds of the weight lost during the active treatment phase was regained within twelve months of stopping, alongside a return toward pre-trial cardiovascular risk markers. Tirzepatide trials show a similar pattern. This is not a personal failure; the biology driving weight gain in the first place (hormonal signalling, appetite regulation, metabolic set-point) reasserts itself once the medicine is gone.
That does not make treatment pointless. It does mean the question of stopping is worth thinking through carefully before you make it.
These medicines work by mimicking gut hormones that your body produces in smaller amounts than it needs to keep weight stable long-term. Remove the medicine, remove the signal. What varies enormously between individuals is how much of that signal they had naturally before starting, how much the lifestyle habits they built during treatment can compensate, and how long treatment ran before stopping.
People who stop after reaching a stable weight and who have genuinely shifted their eating patterns (smaller portions feeling satisfying, processed foods less appealing, regular movement embedded in the week) tend to regain more slowly. If you want to understand in more detail what happens when you stop weight loss injections, including why appetite returns and what the timeline typically looks like, it is worth reading before you make any decision. People who stop because of side effects before reaching a stable dose, or who stop abruptly without planning, tend to find appetite rebounds sharply.
If you are thinking about whether to stop at a particular dose, the considerations around stopping weight loss injections are worth reading before you decide. Equally, if the question is whether a break rather than a full stop makes sense, there is a difference, and what happens when you come off weight loss injections covers how your body responds in the weeks that follow, which can help you and your prescriber plan whether pausing with a restart option makes more sense than stopping outright.
For those still weighing up what treatment even looks like before making any stopping decision, an overview of how weight loss injections work provides useful background. The NHS medicines page for tirzepatide covers what to expect in plain language too.
Talk to your prescriber before stopping. That applies whether you are pausing for surgery, a planned break, a supply issue, or because you feel you have reached your goal. The reasons matter because the plan differs for each one.
If you stop because of a side effect, your prescriber may suggest a dose reduction rather than full cessation. If you stop because you have hit your target weight and feel ready, they can discuss what monitoring makes sense going forward. If you stop because of cost, it is worth knowing that the market for cheaper weight loss injections includes some sellers operating without clinical oversight, understanding what a legitimate prescription service actually costs, and what it includes, is worth a clear look before switching or stopping. At nume, one transparent price covers consultation, prescription, and delivery; there are no auto-renewals, and every repeat order is reviewed by a prescriber individually.
The question of stopping at any point during treatment is more nuanced than it first appears. You can stop at any time medically (there is no physical dependence) but the timing and manner of stopping affects outcomes.
For anyone reconsidering their weight management options more broadly, the weight loss treatment overview sets out what is available and what each approach involves.
The practical takeaway from the trial evidence is that stopping a weight loss injection is a clinical event, not just an admin one. Regain is common and, for many people, significant. That does not mean you must stay on treatment indefinitely, it means the decision deserves the same clinical input as the decision to start.
If you started treatment privately and your prescriber's service does not include aftercare conversations about stopping, that is worth factoring in. At nume, prescribers are available seven days a week for exactly these questions, not just to approve the next order. If you have questions about your treatment or are thinking of stopping, speaking to our prescribers is the right starting point. They can review your situation and give you a plan that fits your goals, not a generic answer.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.